

Ms Madeleine Green
Senior Adviser, Listings Compliance
Australian Securities Exchange
Level 40, Central Park,
152-158 St Georges Terrace
Perth WA 6000
By email: ListingsCompliancePerth@asx.com.au

8 February 2021

Dear Madeleine,

Response to ASX Price and Volume Query

Exopharm Limited (ASX: EX1) ("**Exopharm**" or the "**Company**") refers to your Price and Volume Query letter dated 8 February 2021 and provides the following responses:

1. The Company is not aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities.
2. Not applicable.
3. The Company has no explanation as to why there has been a price and volume change in the trading of the Company's securities.

The Company notes however that there have been recent reports in the media regarding a study using exosomes to treat COVID cases (this study and the media reports are not associated with the Company).

Exopharm, a clinical stage company, is one of the relatively few exosome companies commercialising exosomes as medicines and has previously released information about its SARS-CoV-2 Fortrexo product under development.

4. The Company confirms that it is in compliance with the Listing Rules and, in particular, Listing Rule 3.1.
5. The Company confirms that this response has been authorised and approved by Dr Ian Dixon, Managing Director, having delegated authority from the Board to respond to ASX on disclosure matters.

Yours sincerely,

Elizabeth McGregor
Company Secretary
Tel: (02) 8072 1400

Company and Media Enquiries:

Dr Ian Dixon, MBA
Founder and Managing Director
P: +61 (0)3 9111 0026
ian.dixon@exopharm.com

Join our mailing list to receive updates:
info@exopharm.com
www.exopharm.com
P: +61 (0)3 9111 0026



8 February 2021

Reference: 30624

Ms Elizabeth McGregor
Company Secretary
Exopharm Limited

By email:

Dear Ms McGregor

Exopharm Limited ('EX1'): Price - Query

ASX refers to the following:

- A. The change in the price of EX1's securities from a low of \$0.61 at the close of trade on Friday 5, February 2021 to in-tray high of \$0.795 today, Monday 8 February 2021.
- B. The significant increase in the volume of EX1's securities traded today, Monday 8 February 2021.

Request for information

In light of this, ASX asks EX1 to respond separately to each of the following questions and requests for information:

1. Is EX1 aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?
2. If the answer to question 1 is "yes".
 - (a) Is EX1 relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1? Please note that the recent trading in EX1's securities would suggest to ASX that such information may have ceased to be confidential and therefore EX1 may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is "yes", you need to contact us immediately to discuss the situation.
 - (b) Can an announcement be made immediately? Please note, if the answer to this question is "no", you need to contact us immediately to discuss requesting a trading halt (see below).
 - (c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?
3. If the answer to question 1 is "no", is there any other explanation that EX1 may have for the recent trading in its securities?
4. Please confirm that EX1 is complying with the Listing Rules and, in particular, Listing Rule 3.1.
5. Please confirm that EX1's responses to the questions above have been authorised and approved under its published continuous disclosure policy or otherwise by its board or an officer of EX1 with delegated authority from the board to respond to ASX on disclosure matters.

When and where to send your response

This request is made under Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by no later than **12:00 PM AWST Monday, 8 February 2021**. You should note that if the information requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall

within the exceptions mentioned in Listing Rule 3.1A, EX1's obligation is to disclose the information 'immediately'. This may require the information to be disclosed before the deadline set out in the previous paragraph and may require EX1 to request a trading halt immediately.

Your response should be sent to me by e-mail at ListingsCompliancePerth@asx.com.au. It should not be sent directly to the ASX Market Announcements Office. This is to allow me to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.

Trading halt

If you are unable to respond to this letter by the time specified above, or if the answer to question 1 is "yes" and an announcement cannot be made immediately, you should discuss with us whether it is appropriate to request a trading halt in EX1's securities under Listing Rule 17.1. If you wish a trading halt, you must tell us:

- the reasons for the trading halt;
- how long you want the trading halt to last;
- the event you expect to happen that will end the trading halt;
- that you are not aware of any reason why the trading halt should not be granted; and
- any other information necessary to inform the market about the trading halt, or that we ask for.

We require the request for a trading halt to be in writing. The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted. You can find further information about trading halts in Guidance Note 16 *Trading Halts & Voluntary Suspensions*.

Suspension

If you are unable to respond to this letter by the time specified above, ASX will likely suspend trading in EX1's securities under Listing Rule 17.3.

Listing Rules 3.1 and 3.1A

In responding to this letter, you should have regard to EX1's obligations under Listing Rules 3.1 and 3.1A and also to Guidance Note 8 *Continuous Disclosure*: Listing Rules 3.1 – 3.1B. It should be noted that EX1's obligation to disclose information under Listing Rule 3.1 is not confined to, nor is it necessarily satisfied by, answering the questions set out in this letter.

Release of correspondence between ASX and entity

We reserve the right to release a copy of this letter, your reply and any other related correspondence between us to the market under Listing Rule 18.7A.

Questions

If you have any questions in relation to the above, please do not hesitate to contact me.

Yours sincerely

Madeleine Green
Senior Adviser, Listings Compliance (Perth)